Abstract
This chapter offers comprehensive overview for successful stories for drug repurposing/repositioning for affiliated molecular targets related to the progression of hepatocellular carcinoma (HCC). There are detailed sections about the etiology, pathogenesis, current therapeutic regimen, and affiliated molecular targets contributing to HCC. Drug repositioning has been an emerging successful tool for the drug discovery process within the last decade to repurpose new clinical indications for already existing drugs with established safety and pharmacokinetics profiles. In this chapter, we focused on correlating the adopted strategies for drug repositioning targeting molecular targets affiliated with HCC along with different drugs preidentified for other clinical indication.
| Original language | English (US) |
|---|---|
| Title of host publication | Drug Repurposing in Cancer Therapy |
| Subtitle of host publication | Approaches and Applications |
| Publisher | Elsevier |
| Pages | 213-229 |
| Number of pages | 17 |
| ISBN (Electronic) | 9780128196687 |
| DOIs | |
| State | Published - Jan 1 2020 |
Keywords
- Blinded serendipity-based repositioning
- Computational screening-based repositioning
- Disease network-based repositioning
- Drug repositioning
- Drug repurposing
- Hepatocellular carcinoma
- High-throughput screening-based repositioning
- Systems biology
ASJC Scopus subject areas
- General Agricultural and Biological Sciences
- General Biochemistry, Genetics and Molecular Biology